TREMFYA® (guselkumab) demonstrates superiority versus STELARA® (ustekinumab) in Phase 3 Crohn's disease program
Data from GALAXI 2 & 3 showed TREMFYA® was superior to STELARA ® in all pooled endoscopic endpoints WASHINGTON, May 21, 2024 /PRNewswire/ -- Johnson & Johnson today announced the first Phase 3 results for TREMFYA® (guselkumab) in adult …